CeNeRx’s Antidepressant TriRima Shows Key Safety Benefit in Study

CeNeRx BioPharma, Inc., Tuesday announced that a new formulation of TriRima, its lead agent for treatment resistant depression, showed excellent safety in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors.
Earth Times